Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol’s Taxol, Sanofi’s Taxotere Among Latest Victims Of China Price Cuts

This article was originally published in The Pink Sheet Daily

Executive Summary

China’s NDRC cuts retail ceiling prices on 95 cancer, hematology and immunology drugs, with more cuts expected next year.

You may also be interested in...



With Latest Round Of Cuts, China Continues March To Narrow Gap Between Big Pharma And Local Generics

SHANGHAI - As expected, China's powerful National Development and Reform Commission announced Aug. 5 a new round of price cuts, this time targeting hormone and endocrinology drugs and central nervous system drugs, with an average cut of roughly 14%, according to analysts

Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields

SHANGHAI - While Beijing is hosting China's National People's Congress this week to discuss and design its next Five-Year Plan, China's powerful National Development and Reform Commission announced another round of price cuts on antibiotics and cardiovascular drugs with an average price reduction of 21%, less than the rumored 30-40% cuts, but still a blow to Big Pharma

China's NDRC Releases First Set Of Price Cuts; MNCs See Deepest Cuts As Expected

SHANGHAI - China's National Development and Reform Commission has released long-awaited price cuts that will mostly affect multinational pharma companies

Topics

Related Companies

UsernamePublicRestriction

Register

PS074675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel